0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Global Market Insights and Sales Trends 2024
Published Date: December 2023
|
Report Code: QYRE-Auto-27S13641
Home | Market Reports | Health| Men s Health
Global Castration Resistant Prostate Cancer CRPC HRPCA Therapeutics Market Research Report 2023
BUY CHAPTERS

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Global Market Insights and Sales Trends 2024

Code: QYRE-Auto-27S13641
Report
December 2023
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Market Size

The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market size is expected to reach US$ 11190 million by 2029, growing at a CAGR of 5.2% from 2023 to 2029.

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics -  Market

Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Market

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications. The market growth would pivot around the novel breakthrough treatments responsible for reaping survival benefits. The survival benefit would be instrumental in governing the peak sales and market penetration of novel approved drugs.
Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth. Further, untapped CRPC market in the Asia-Pacific and LAMEA region would also accelerate the overall market growth during the forecast period. Untapped non-metastatic CRPC settings would further bolster the market growth. On the other hand, factors such as premium pricing of CRPC drugs, uncertain reimbursement policies and lack of differentiation in mechanism of action among the approved and novel agents are likely to curtail the market growth.
The market is mainly driven by the significant applications of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics in various end use industries. The expanding demands from the Hospitals & Clinics, Home Settings and Ambulatory Surgical Centers (ASCs),, are propelling Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market. Oral Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Injectable Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics covered in this report include Astellas Inc., Johnson & Johnson, Sanofi S.A, Dendreon Corporation and Bayer AG, etc.
The global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, Segment by Type:
Oral Therapy
Injectable Therapy
Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics market, by Application
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)

Scope of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Market Report

Report Metric Details
Report Name Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Market
Forecasted market size in 2029 US$ 11190 million
CAGR 5.2%
Forecasted years 2023 - 2029
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter Four: Detailed analysis of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
  • Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
  • Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter Twelve: Research Finding/Conclusion

FAQ for this report

What is the Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Market size in 2029?

Ans: The Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics - Market size in 2029 will be US$ 11190 million.

1 Market Overview of Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics
1.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview
1.1.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Scope
1.1.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Status and Outlook
1.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2018-2029)
1.4 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029)
2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market by Type
2.1 Introduction
2.1.1 Oral Therapy
2.1.2 Injectable Therapy
2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Type (2018-2029)
3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals & Clinics
3.1.2 Home Settings
3.1.3 Ambulatory Surgical Centers (ASCs)
3.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Breakdown by Application (2018-2029)
4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Competition Analysis by Players
4.1 Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2022)
4.3 Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market
4.4 Global Top Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Headquarters and Area Served
4.5 Key Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astellas Inc.
5.1.1 Astellas Inc. Profile
5.1.2 Astellas Inc. Main Business
5.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Astellas Inc. Recent Developments
5.2 Johnson & Johnson
5.2.1 Johnson & Johnson Profile
5.2.2 Johnson & Johnson Main Business
5.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Johnson & Johnson Recent Developments
5.3 Sanofi S.A
5.3.1 Sanofi S.A Profile
5.3.2 Sanofi S.A Main Business
5.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Dendreon Corporation Recent Developments
5.4 Dendreon Corporation
5.4.1 Dendreon Corporation Profile
5.4.2 Dendreon Corporation Main Business
5.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Dendreon Corporation Recent Developments
5.5 Bayer AG
5.5.1 Bayer AG Profile
5.5.2 Bayer AG Main Business
5.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
5.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Bayer AG Recent Developments
6 North America
6.1 North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Dynamics
11.1 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Industry Trends
11.2 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers
11.3 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
11.4 Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
List of Tables
    Table 1. Global Market Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (US$ Million) Comparison by Region 2018 VS 2022 VS 2029
    Table 2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 3. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Share by Region (2018-2023)
    Table 4. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 5. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size Share by Region (2024-2029)
    Table 6. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (US$ Million) by Type: 2018 VS 2022 VS 2029
    Table 7. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Type (2018-2023) & (US$ Million)
    Table 8. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2018-2023)
    Table 9. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 10. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2024-2029)
    Table 11. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 12. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 13. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 14. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 15. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 16. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 17. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 18. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 19. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2018-2023) & (US$ Million)
    Table 20. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Type (2024-2029) & (US$ Million)
    Table 21. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (US$ Million) by Application: 2018 VS 2022 VS 2029
    Table 22. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Application (2018-2023) & (US$ Million)
    Table 23. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2018-2023)
    Table 24. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 25. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2024-2029)
    Table 26. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 27. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 28. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 29. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 30. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 31. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 32. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 33. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 34. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2018-2023) & (US$ Million)
    Table 35. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue by Application (2024-2029) & (US$ Million)
    Table 36. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue (US$ Million) by Players (2018-2023)
    Table 37. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Players (2018-2023)
    Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics as of 2022)
    Table 39. Date of Key Players Enter into Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market
    Table 40. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Key Players Headquarters and Area Served
    Table 41. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Product Solution and Service
    Table 42. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Players Market Concentration Ratio (CR5 and HHI)
    Table 43. Mergers & Acquisitions, Expansion Plans
    Table 44. Astellas Inc. Basic Information List
    Table 45. Astellas Inc. Description and Business Overview
    Table 46. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 47. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Astellas Inc. (2018-2023)
    Table 48. Astellas Inc. Recent Developments
    Table 49. Johnson & Johnson Basic Information List
    Table 50. Johnson & Johnson Description and Business Overview
    Table 51. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 52. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Johnson & Johnson (2018-2023)
    Table 53. Johnson & Johnson Recent Developments
    Table 54. Sanofi S.A Basic Information List
    Table 55. Sanofi S.A Description and Business Overview
    Table 56. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 57. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Sanofi S.A (2018-2023)
    Table 58. Sanofi S.A Recent Developments
    Table 59. Dendreon Corporation Basic Information List
    Table 60. Dendreon Corporation Description and Business Overview
    Table 61. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 62. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Dendreon Corporation (2018-2023)
    Table 63. Dendreon Corporation Recent Developments
    Table 64. Bayer AG Basic Information List
    Table 65. Bayer AG Description and Business Overview
    Table 66. Bayer AG Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Products, Services and Solutions
    Table 67. Revenue (US$ Million) in Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Business of Bayer AG (2018-2023)
    Table 68. Bayer AG Recent Developments
    Table 69. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 70. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 71. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 72. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 73. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 74. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2018-2023) & (US$ Million)
    Table 75. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Region (2024-2029) & (US$ Million)
    Table 76. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2018-2023)
    Table 77. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2024-2029)
    Table 78. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 79. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 80. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 81. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 82. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2018-2023) & (US$ Million)
    Table 83. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size by Country (2024-2029) & (US$ Million)
    Table 84. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Trends
    Table 85. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Drivers
    Table 86. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Challenges
    Table 87. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Restraints
    Table 88. Research Programs/Design for This Report
    Table 89. Key Data Information from Secondary Sources
    Table 90. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Year-over-Year 2018-2029 & (US$ Million)
    Figure 2. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (US$ Million), 2018 VS 2022 VS 2029
    Figure 3. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Regions: 2022 VS 2029
    Figure 4. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Forecasted Market Size Share by Region (2024-2029)
    Figure 5. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 6. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 7. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 8. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 9. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Growth Rate (2018-2029) & (US$ Million)
    Figure 10. Product Picture of Oral Therapy
    Figure 11. Global Oral Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 12. Product Picture of Injectable Therapy
    Figure 13. Global Injectable Therapy Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 14. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Share by Type: 2022 & 2029
    Figure 15. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 16. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 17. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 18. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 19. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Type (2018-2029)
    Figure 20. Hospitals & Clinics Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 21. Home Settings Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 22. Ambulatory Surgical Centers (ASCs) Market Size (US$ Million) & YoY Growth (2018-2029)
    Figure 23. Global Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size Share by Application: 2022 & 2029
    Figure 24. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 25. Europe Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 26. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 27. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 28. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Revenue Market Share by Application (2018-2029)
    Figure 29. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 30. Global Top 5 and Top 10 Players Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share in 2022
    Figure 31. North America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2018-2029)
    Figure 32. U.S. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 33. Canada Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 34. Germany Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 35. France Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 36. U.K. Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 37. Italy Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 38. Russia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 39. Nordic Countries Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 40. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Region (2018-2029)
    Figure 41. China Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 42. Japan Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 43. South Korea Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 44. Southeast Asia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 45. India Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 46. Australia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 47. Latin America Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2018-2029)
    Figure 48. Mexico Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 49. Brazil Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 50. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Share by Country (2018-2029)
    Figure 51. Turkey Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 52. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 53. UAE Castration-Resistant Prostate Cancer (CRPC) & HRPCA Therapeutics Market Size (2018-2029) & (US$ Million)
    Figure 54. Bottom-up and Top-down Approaches for This Report
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3350

This license allows only one user to access the PDF.
Electronic (PDF)

$5025

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$6700

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS